CAR T cell therapy selectively depletes disease-driving mutant calreticulin cells in xenotransplants and human organoid models of myelofibrosis
Alexandros Rampotas, Zoë C. Wong, Isaac Gannon, Charlotte K. Brierley, Yuqi Shen, Camélia Benlabiod, Ashlyn Chee, Saif Khan, Nawshad Hayder, Gordon Weng-Kit Cheung, Marina Mitsikakou, Eleanor Murphy, Mathieu Ferrari, Anna M. Bulek, Antonio Rodriguez-Romera, , Martin A. Pulè
A first-in-class CAR T-cell therapy targeting mutant calreticulin selectively depletes malignant stem cells in vivo and in fibrotic human organoids.
Science Translational Medicine · Jul 1, 2026Peer-reviewedCancer Biology